APO Research
Talk to an analyst

APO RESEARCH · REPORT

Friedreich Ataxia Drug

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Friedreich Ataxia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

19 December 2025194 pages

Choose your research edition.

Industry ResearchFriedreich Ataxia Drug Industry Research Report 2026138 pages · $2,950 USDIndustry Growth & TrendsGlobal Friedreich Ataxia Drug Industry Growth and Trends Forecast to 2032117 pages · $3,450 USDMarket StructureGlobal Friedreich Ataxia Drug Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032194 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Friedreich Ataxia Drug Market Outlook and Growth Opportunities 2026196 pages · $4,250 USDMarket Analysis & ForecastGlobal Friedreich Ataxia Drug Market Analysis and Forecast 2026-2032192 pages · $4,950 USD

Market perspective

The global Friedreich Ataxia Drug market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Friedreich Ataxia Drug is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Friedreich Ataxia Drug include Takeda, Pfizer Inc, Voyager Therapeutics Inc, STATegics Inc, Retrotope Inc, Reata Pharmaceuticals Inc, RaNA Therapeutics Inc, ProQR Therapeutics NV and Ixchel Pharma LLC, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Friedreich Ataxia Drug market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Friedreich Ataxia Drug and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Friedreich Ataxia Drug sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Friedreich Ataxia Drug market size, projected growth trends, production technologies, key applications, and end-use industries.

Friedreich Ataxia Drug Segment by Company

Takeda

Pfizer Inc

Voyager Therapeutics Inc

STATegics Inc

Retrotope Inc

Reata Pharmaceuticals Inc

RaNA Therapeutics Inc

ProQR Therapeutics NV

Ixchel Pharma LLC

Forward Pharma A/S

Catabasis Pharmaceuticals, Inc.

Cardero Therapeutics Inc

Biovista Inc.

BioMarin Pharmaceutical Inc.

Adverum Biotechnologies Inc

Friedreich Ataxia Drug Segment by Type

BVA-202

BHV-4157

AGIL-FA

ADVM-063

Others

Friedreich Ataxia Drug Segment by Application

Clinic

Hospital

Others

Friedreich Ataxia Drug Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Friedreich Ataxia Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Friedreich Ataxia Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Friedreich Ataxia Drug.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Friedreich Ataxia Drug market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Friedreich Ataxia Drug manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Friedreich Ataxia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Friedreich Ataxia Drug in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Friedreich Ataxia Drug Industry Trends Table 2. Friedreich Ataxia Drug Industry Drivers Table 3. Friedreich Ataxia Drug Industry Opportunities and Challenges Table 4. Friedreich Ataxia Drug Industry Restraints Table 5. Global Friedreich Ataxia Drug Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Friedreich Ataxia Drug Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Friedreich Ataxia Drug Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Friedreich Ataxia Drug Sales Market Share by Manufacturers Table 9. Global Friedreich Ataxia Drug Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Friedreich Ataxia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Friedreich Ataxia Drug Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Friedreich Ataxia Drug Manufacturers, Product Type & Application Table 13. Global Friedreich Ataxia Drug Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Friedreich Ataxia Drug by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of BVA-202 Table 17. Major Manufacturers of BHV-4157 Table 18. Major Manufacturers of AGIL-FA Table 19. Major Manufacturers of ADVM-063 Table 20. Major Manufacturers of Others Table 21. Global Friedreich Ataxia Drug Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Friedreich Ataxia Drug Sales by Type (2021-2026) & (K Units) Table 23. Global Friedreich Ataxia Drug Sales by Type (2027-2032) & (K Units) Table 24. Global Friedreich Ataxia Drug Sales Market Share by Type (2021-2026) Table 25. Global Friedreich Ataxia Drug Sales Market Share by Type (2027-2032) Table 26. Global Friedreich Ataxia Drug Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Friedreich Ataxia Drug Revenue by Type (2021-2026) & (K Units) Table 28. Global Friedreich Ataxia Drug Revenue by Type (2027-2032) & (K Units) Table 29. Global Friedreich Ataxia Drug Revenue Market Share by Type (2021-2026) Table 30. Global Friedreich Ataxia Drug Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Clinic Table 32. Major Manufacturers of Hospital Table 33. Major Manufacturers of Others Table 34. Global Friedreich Ataxia Drug Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Friedreich Ataxia Drug Sales by Application (2021-2026) & (K Units) Table 36. Global Friedreich Ataxia Drug Sales by Application (2027-2032) & (K Units) Table 37. Global Friedreich Ataxia Drug Sales Market Share by Application (2021-2026) Table 38. Global Friedreich Ataxia Drug Sales Market Share by Application (2027-2032) Table 39. Global Friedreich Ataxia Drug Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Friedreich Ataxia Drug Revenue by Application (2021-2026) & (K Units) Table 41. Global Friedreich Ataxia Drug Revenue by Application (2027-2032) & (K Units) Table 42. Global Friedreich Ataxia Drug Revenue Market Share by Application (2021-2026) Table 43. Global Friedreich Ataxia Drug Revenue Market Share by Application (2027-2032) Table 44. Global Friedreich Ataxia Drug Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Friedreich Ataxia Drug Sales by Region (2021-2026) & (K Units) Table 46. Global Friedreich Ataxia Drug Sales Market Share by Region (2021-2026) Table 47. Global Friedreich Ataxia Drug Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Friedreich Ataxia Drug Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 51. North America Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 52. Europe Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 54. Europe Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Friedreich Ataxia Drug Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Friedreich Ataxia Drug Sales by Country (2027-2032) & (K Units) Table 61. Global Friedreich Ataxia Drug Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Friedreich Ataxia Drug Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Friedreich Ataxia Drug Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Friedreich Ataxia Drug Revenue Market Share by Region (2021-2026) Table 65. Global Friedreich Ataxia Drug Revenue Market Share by Region (2027-2032) Table 66. Takeda Company Information Table 67. Takeda Business Overview Table 68. Takeda Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Takeda Friedreich Ataxia Drug Product Portfolio Table 70. Takeda Recent Development Table 71. Pfizer Inc Company Information Table 72. Pfizer Inc Business Overview Table 73. Pfizer Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Pfizer Inc Friedreich Ataxia Drug Product Portfolio Table 75. Pfizer Inc Recent Development Table 76. Voyager Therapeutics Inc Company Information Table 77. Voyager Therapeutics Inc Business Overview Table 78. Voyager Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 80. Voyager Therapeutics Inc Recent Development Table 81. STATegics Inc Company Information Table 82. STATegics Inc Business Overview Table 83. STATegics Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. STATegics Inc Friedreich Ataxia Drug Product Portfolio Table 85. STATegics Inc Recent Development Table 86. Retrotope Inc Company Information Table 87. Retrotope Inc Business Overview Table 88. Retrotope Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Retrotope Inc Friedreich Ataxia Drug Product Portfolio Table 90. Retrotope Inc Recent Development Table 91. Reata Pharmaceuticals Inc Company Information Table 92. Reata Pharmaceuticals Inc Business Overview Table 93. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio Table 95. Reata Pharmaceuticals Inc Recent Development Table 96. RaNA Therapeutics Inc Company Information Table 97. RaNA Therapeutics Inc Business Overview Table 98. RaNA Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 100. RaNA Therapeutics Inc Recent Development Table 101. ProQR Therapeutics NV Company Information Table 102. ProQR Therapeutics NV Business Overview Table 103. ProQR Therapeutics NV Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio Table 105. ProQR Therapeutics NV Recent Development Table 106. Ixchel Pharma LLC Company Information Table 107. Ixchel Pharma LLC Business Overview Table 108. Ixchel Pharma LLC Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio Table 110. Ixchel Pharma LLC Recent Development Table 111. Forward Pharma A/S Company Information Table 112. Forward Pharma A/S Business Overview Table 113. Forward Pharma A/S Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio Table 115. Forward Pharma A/S Recent Development Table 116. Catabasis Pharmaceuticals, Inc. Company Information Table 117. Catabasis Pharmaceuticals, Inc. Business Overview Table 118. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio Table 120. Catabasis Pharmaceuticals, Inc. Recent Development Table 121. Cardero Therapeutics Inc Company Information Table 122. Cardero Therapeutics Inc Business Overview Table 123. Cardero Therapeutics Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio Table 125. Cardero Therapeutics Inc Recent Development Table 126. Biovista Inc. Company Information Table 127. Biovista Inc. Business Overview Table 128. Biovista Inc. Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. Biovista Inc. Friedreich Ataxia Drug Product Portfolio Table 130. Biovista Inc. Recent Development Table 131. BioMarin Pharmaceutical Inc. Company Information Table 132. BioMarin Pharmaceutical Inc. Business Overview Table 133. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio Table 135. BioMarin Pharmaceutical Inc. Recent Development Table 136. Adverum Biotechnologies Inc Company Information Table 137. Adverum Biotechnologies Inc Business Overview Table 138. Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio Table 140. Adverum Biotechnologies Inc Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Friedreich Ataxia Drug Distributors List Table 144. Friedreich Ataxia Drug Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Friedreich Ataxia Drug Product Image Figure 2. Global Friedreich Ataxia Drug Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Friedreich Ataxia Drug Market Size (2021-2032) & (US$ Million) Figure 4. Global Friedreich Ataxia Drug Sales (2021-2032) & (K Units) Figure 5. Global Friedreich Ataxia Drug Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Friedreich Ataxia Drug Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. BVA-202 Image Figure 9. BHV-4157 Image Figure 10. AGIL-FA Image Figure 11. ADVM-063 Image Figure 12. Others Image Figure 13. Global Friedreich Ataxia Drug Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Friedreich Ataxia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Friedreich Ataxia Drug Sales Market Share by Type (2021-2032) Figure 16. Global Friedreich Ataxia Drug Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Friedreich Ataxia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Friedreich Ataxia Drug Revenue Market Share by Type (2021-2032) Figure 19. Clinic Image Figure 20. Hospital Image Figure 21. Others Image Figure 22. Global Friedreich Ataxia Drug Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Friedreich Ataxia Drug Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Friedreich Ataxia Drug Sales Market Share by Application (2021-2032) Figure 25. Global Friedreich Ataxia Drug Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Friedreich Ataxia Drug Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Friedreich Ataxia Drug Revenue Market Share by Application (2021-2032) Figure 28. North America Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 30. U.S. Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 35. Germany Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 42. China Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Friedreich Ataxia Drug Sales Market Share by Country (2021-2032) Figure 50. Brazil Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Friedreich Ataxia Drug Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Friedreich Ataxia Drug Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Friedreich Ataxia Drug Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Friedreich Ataxia Drug Revenue (2021-2032) & (US$ Million) Figure 61. North America Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Friedreich Ataxia Drug Revenue (2021-2032) & (US$ Million) Figure 63. Europe Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Friedreich Ataxia Drug Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Friedreich Ataxia Drug Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Friedreich Ataxia Drug Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Friedreich Ataxia Drug Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • BVA-202
  • BHV-4157
  • AGIL-FA
  • ADVM-063
  • Others
Applications
  • Clinic
  • Hospital
  • Others
Companies covered
  • Takeda
  • Pfizer Inc
  • Voyager Therapeutics Inc
  • STATegics Inc
  • Retrotope Inc
  • Reata Pharmaceuticals Inc
  • RaNA Therapeutics Inc
  • ProQR Therapeutics NV
  • Ixchel Pharma LLC
  • Forward Pharma A/S
  • Catabasis Pharmaceuticals, Inc.
  • Cardero Therapeutics Inc
  • Biovista Inc.
  • BioMarin Pharmaceutical Inc.
  • Adverum Biotechnologies Inc

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Friedreich Ataxia Drug Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Friedreich Ataxia Drug Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Friedreich Ataxia Drug Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Friedreich Ataxia Drug Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Friedreich Ataxia Drug Market Dynamics
  1. 2.1 Friedreich Ataxia Drug Industry Trends
  2. 2.2 Friedreich Ataxia Drug Industry Drivers
  3. 2.3 Friedreich Ataxia Drug Industry Opportunities and Challenges
  4. 2.4 Friedreich Ataxia Drug Industry Restraints
3 Friedreich Ataxia Drug Market by Manufacturers
  1. 3.1 Global Friedreich Ataxia Drug Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Friedreich Ataxia Drug Sales by Manufacturers (2021-2026)
  3. 3.3 Global Friedreich Ataxia Drug Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Friedreich Ataxia Drug Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Friedreich Ataxia Drug Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Friedreich Ataxia Drug Manufacturers, Product Type & Application
  7. 3.7 Global Friedreich Ataxia Drug Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Friedreich Ataxia Drug Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Friedreich Ataxia Drug Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Friedreich Ataxia Drug Tier 1, Tier 2, and Tier 3
4 Friedreich Ataxia Drug Market by Type
  1. 4.1 Friedreich Ataxia Drug Type Introduction
  2. 4.1.1 BVA-202
  3. 4.1.2 BHV-4157
  4. 4.1.3 AGIL-FA
  5. 4.1.4 ADVM-063
  6. 4.1.5 Others
  7. 4.2 Global Friedreich Ataxia Drug Sales by Type
  8. 4.2.1 Global Friedreich Ataxia Drug Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Friedreich Ataxia Drug Sales by Type (2021-2032)
  10. 4.2.3 Global Friedreich Ataxia Drug Sales Market Share by Type (2021-2032)
  11. 4.3 Global Friedreich Ataxia Drug Revenue by Type
  12. 4.3.1 Global Friedreich Ataxia Drug Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Friedreich Ataxia Drug Revenue by Type (2021-2032)
  14. 4.3.3 Global Friedreich Ataxia Drug Revenue Market Share by Type (2021-2032)
5 Friedreich Ataxia Drug Market by Application
  1. 5.1 Friedreich Ataxia Drug Application Introduction
  2. 5.1.1 Clinic
  3. 5.1.2 Hospital
  4. 5.1.3 Others
  5. 5.2 Global Friedreich Ataxia Drug Sales by Application
  6. 5.2.1 Global Friedreich Ataxia Drug Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Friedreich Ataxia Drug Sales by Application (2021-2032)
  8. 5.2.3 Global Friedreich Ataxia Drug Sales Market Share by Application (2021-2032)
  9. 5.3 Global Friedreich Ataxia Drug Revenue by Application
  10. 5.3.1 Global Friedreich Ataxia Drug Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Friedreich Ataxia Drug Revenue by Application (2021-2032)
  12. 5.3.3 Global Friedreich Ataxia Drug Revenue Market Share by Application (2021-2032)
6 Global Friedreich Ataxia Drug Sales by Region
  1. 6.1 Global Friedreich Ataxia Drug Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Friedreich Ataxia Drug Sales by Region (2021-2032)
  3. 6.2.1 Global Friedreich Ataxia Drug Sales by Region (2021-2026)
  4. 6.2.2 Global Friedreich Ataxia Drug Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Friedreich Ataxia Drug Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Friedreich Ataxia Drug Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Friedreich Ataxia Drug Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Friedreich Ataxia Drug Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Friedreich Ataxia Drug Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Friedreich Ataxia Drug Revenue by Region
  1. 7.1 Global Friedreich Ataxia Drug Revenue by Region
  2. 7.1.1 Global Friedreich Ataxia Drug Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Friedreich Ataxia Drug Revenue by Region (2021-2026)
  4. 7.1.3 Global Friedreich Ataxia Drug Revenue by Region (2027-2032)
  5. 7.1.4 Global Friedreich Ataxia Drug Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Friedreich Ataxia Drug Revenue (2021-2032)
  8. 7.2.2 North America Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Friedreich Ataxia Drug Revenue (2021-2032)
  11. 7.3.2 Europe Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Friedreich Ataxia Drug Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Friedreich Ataxia Drug Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Friedreich Ataxia Drug Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Takeda
  2. 8.1.1 Takeda Company Information
  3. 8.1.2 Takeda Business Overview
  4. 8.1.3 Takeda Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Takeda Friedreich Ataxia Drug Product Portfolio
  6. 8.1.5 Takeda Recent Developments
  7. 8.2 Pfizer Inc
  8. 8.2.1 Pfizer Inc Company Information
  9. 8.2.2 Pfizer Inc Business Overview
  10. 8.2.3 Pfizer Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Pfizer Inc Friedreich Ataxia Drug Product Portfolio
  12. 8.2.5 Pfizer Inc Recent Developments
  13. 8.3 Voyager Therapeutics Inc
  14. 8.3.1 Voyager Therapeutics Inc Company Information
  15. 8.3.2 Voyager Therapeutics Inc Business Overview
  16. 8.3.3 Voyager Therapeutics Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Voyager Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  18. 8.3.5 Voyager Therapeutics Inc Recent Developments
  19. 8.4 STATegics Inc
  20. 8.4.1 STATegics Inc Company Information
  21. 8.4.2 STATegics Inc Business Overview
  22. 8.4.3 STATegics Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 STATegics Inc Friedreich Ataxia Drug Product Portfolio
  24. 8.4.5 STATegics Inc Recent Developments
  25. 8.5 Retrotope Inc
  26. 8.5.1 Retrotope Inc Company Information
  27. 8.5.2 Retrotope Inc Business Overview
  28. 8.5.3 Retrotope Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Retrotope Inc Friedreich Ataxia Drug Product Portfolio
  30. 8.5.5 Retrotope Inc Recent Developments
  31. 8.6 Reata Pharmaceuticals Inc
  32. 8.6.1 Reata Pharmaceuticals Inc Company Information
  33. 8.6.2 Reata Pharmaceuticals Inc Business Overview
  34. 8.6.3 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Reata Pharmaceuticals Inc Friedreich Ataxia Drug Product Portfolio
  36. 8.6.5 Reata Pharmaceuticals Inc Recent Developments
  37. 8.7 RaNA Therapeutics Inc
  38. 8.7.1 RaNA Therapeutics Inc Company Information
  39. 8.7.2 RaNA Therapeutics Inc Business Overview
  40. 8.7.3 RaNA Therapeutics Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 RaNA Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  42. 8.7.5 RaNA Therapeutics Inc Recent Developments
  43. 8.8 ProQR Therapeutics NV
  44. 8.8.1 ProQR Therapeutics NV Company Information
  45. 8.8.2 ProQR Therapeutics NV Business Overview
  46. 8.8.3 ProQR Therapeutics NV Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 ProQR Therapeutics NV Friedreich Ataxia Drug Product Portfolio
  48. 8.8.5 ProQR Therapeutics NV Recent Developments
  49. 8.9 Ixchel Pharma LLC
  50. 8.9.1 Ixchel Pharma LLC Company Information
  51. 8.9.2 Ixchel Pharma LLC Business Overview
  52. 8.9.3 Ixchel Pharma LLC Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Ixchel Pharma LLC Friedreich Ataxia Drug Product Portfolio
  54. 8.9.5 Ixchel Pharma LLC Recent Developments
  55. 8.10 Forward Pharma A/S
  56. 8.10.1 Forward Pharma A/S Company Information
  57. 8.10.2 Forward Pharma A/S Business Overview
  58. 8.10.3 Forward Pharma A/S Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Forward Pharma A/S Friedreich Ataxia Drug Product Portfolio
  60. 8.10.5 Forward Pharma A/S Recent Developments
  61. 8.11 Catabasis Pharmaceuticals, Inc.
  62. 8.11.1 Catabasis Pharmaceuticals, Inc. Company Information
  63. 8.11.2 Catabasis Pharmaceuticals, Inc. Business Overview
  64. 8.11.3 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Catabasis Pharmaceuticals, Inc. Friedreich Ataxia Drug Product Portfolio
  66. 8.11.5 Catabasis Pharmaceuticals, Inc. Recent Developments
  67. 8.12 Cardero Therapeutics Inc
  68. 8.12.1 Cardero Therapeutics Inc Company Information
  69. 8.12.2 Cardero Therapeutics Inc Business Overview
  70. 8.12.3 Cardero Therapeutics Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Cardero Therapeutics Inc Friedreich Ataxia Drug Product Portfolio
  72. 8.12.5 Cardero Therapeutics Inc Recent Developments
  73. 8.13 Biovista Inc.
  74. 8.13.1 Biovista Inc. Company Information
  75. 8.13.2 Biovista Inc. Business Overview
  76. 8.13.3 Biovista Inc. Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 Biovista Inc. Friedreich Ataxia Drug Product Portfolio
  78. 8.13.5 Biovista Inc. Recent Developments
  79. 8.14 BioMarin Pharmaceutical Inc.
  80. 8.14.1 BioMarin Pharmaceutical Inc. Company Information
  81. 8.14.2 BioMarin Pharmaceutical Inc. Business Overview
  82. 8.14.3 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 BioMarin Pharmaceutical Inc. Friedreich Ataxia Drug Product Portfolio
  84. 8.14.5 BioMarin Pharmaceutical Inc. Recent Developments
  85. 8.15 Adverum Biotechnologies Inc
  86. 8.15.1 Adverum Biotechnologies Inc Company Information
  87. 8.15.2 Adverum Biotechnologies Inc Business Overview
  88. 8.15.3 Adverum Biotechnologies Inc Friedreich Ataxia Drug Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Adverum Biotechnologies Inc Friedreich Ataxia Drug Product Portfolio
  90. 8.15.5 Adverum Biotechnologies Inc Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Friedreich Ataxia Drug Value Chain Analysis
  2. 9.1.1 Friedreich Ataxia Drug Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Friedreich Ataxia Drug Production Mode & Process
  6. 9.2 Friedreich Ataxia Drug Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Friedreich Ataxia Drug Distributors
  9. 9.2.3 Friedreich Ataxia Drug Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst